Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$212.02 - $267.71 $504,395 - $636,882
-2,379 Reduced 48.76%
2,500 $539,000
Q4 2023

Feb 14, 2024

SELL
$222.59 - $267.94 $3.81 Million - $4.59 Million
-17,121 Reduced 77.82%
4,879 $1.26 Million
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $5.57 Million - $6.29 Million
22,000 New
22,000 $5.65 Million
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $396,385 - $451,665
1,545 Added 21.87%
8,610 $2.39 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $281,470 - $341,992
1,115 Added 18.74%
7,065 $0
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $1.16 Million - $1.6 Million
5,950 New
5,950 $1.59 Billion

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $29.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.